MarketCap
Facebook
X
Telegram
Apyx Medical Corporation Income Statement 2025-2008 | APYX
Brief overview of profit and loss at Apyx Medical Corporation
This overview is based on financial performance over the past five years. The revenue attributed to Apyx Medical Corporation moved from 27.7 million dollars to 52.8 million dollars between the two endpoints. Across the full period, sales moved by +90.7%; the average annual rate was 13.8%. The trajectory reflects meaningful expansion of the business.
Gross profit changed from $17.5 million to $33 million (+88.8%). There was no major divergence between sales and cost of revenue. Comparing the endpoints gives gross margins of 63.2% and 62.5%. The economics of the core business remained steady.
EBITDA was −19.2 million dollars at the beginning and −5.8 million dollars at the end of the period (+69.8%). Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from −69.3% to −11%. A wider margin confirms stronger operating efficiency.
The net financial result changed from −11.9 million dollars to −11.2 million dollars. The loss narrowed, although sustainable profitability has not yet returned.
Market value was $318 million at the start and $142 million at the end. Market value lagged the financial performance.
Overall conclusion
The results present an uneven picture without one dominant signal. The positive side is supported by steady gross profitability, a stronger final result and sales growth. The most visible risks are a weaker market valuation and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Apyx Medical Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
142 M | 123 M | 45.7 M | 96.6 M | 440 M | 318 M | 258 M | 287 M | - | - | - | - | - | - | - | - | - | - |
Shares |
41.1 M | 35.5 M | 34.6 M | 34.5 M | 34.3 M | 34.2 M | 34.1 M | 33.2 M | - | - | - | - | - | - | - | 17.4 M | 16.9 M | - |
Historical Prices |
3.45 | 3.45 | 1.32 | 2.8 | 12.8 | 7.2 | 8.46 | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-11.2 M | -23.5 M | -18.7 M | -23.2 M | -15.2 M | -11.9 M | -19.7 M | 64 M | -5.06 M | -3.95 M | -5.37 M | -17.3 M | -4.34 M | 617 K | 109 K | -1.54 M | 596 K | - |
Revenue |
52.8 M | 48.1 M | 52.3 M | 44.5 M | 48.5 M | 27.7 M | 28.2 M | 16.7 M | 38.9 M | 36.6 M | 29.5 M | 27.7 M | 23.7 M | 27.7 M | 25.4 M | - | - | - |
Cost of Revenue |
19.8 M | 18.7 M | 18.6 M | 15.4 M | 14.9 M | 10.2 M | 9.14 M | 5.78 M | 3.28 M | 3.7 M | 17 M | 18.7 M | 14.5 M | 16.3 M | 14.7 M | 14.2 M | 15.1 M | - |
Gross Profit |
33 M | 29.4 M | 33.8 M | 29.1 M | 33.6 M | 17.5 M | 19.1 M | 10.8 M | 19.8 M | 17.9 M | 12.6 M | 8.99 M | 9.2 M | 11.3 M | 10.7 M | 9.99 M | 11.9 M | - |
Operating Income |
-6.45 M | -18.8 M | -17.3 M | -23.6 M | -14.4 M | -20.1 M | -20.9 M | -14.3 M | -13.9 M | -11.4 M | -6.99 M | -5.85 M | -3.67 M | 1.05 M | -18 K | -2.75 M | 715 K | - |
Interest Expense |
- | -161 K | 2.48 M | 15 K | 10 K | 46 K | 8 K | 104 K | 136 K | 158 K | 1.64 M | -7.44 M | -2.29 M | -212 K | 50 K | 290 K | -52 K | - |
EBITDA |
-5.79 M | -18.2 M | -16.6 M | -22.7 M | -13.5 M | -19.2 M | -20.1 M | -12.2 M | -3.04 M | -3.06 M | -6.17 M | -4.97 M | -1.2 M | 1.9 M | 157 K | -2.02 M | 1.49 M | - |
Operating Expenses |
39.5 M | 48.2 M | 53.7 M | 52.7 M | 48 M | 37.6 M | 40 M | 23.7 M | 23.5 M | 21.7 M | 19.5 M | 14.8 M | 11.2 M | 10.3 M | 11.5 M | - | - | - |
General and Administrative Expenses |
15.8 M | 18.9 M | 22.2 M | 20.5 M | 18.6 M | 33.7 M | 36.2 M | 21.2 M | 9.68 M | 10.5 M | 8.97 M | 6.74 M | 5.07 M | 4.62 M | 10.3 M | 4.89 M | 4.66 M | - |
All numbers in USD currency
Quarterly Income Statement Apyx Medical Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
43.8 M | 43.7 M | 40.7 M | 40.7 M | 40.7 M | 37.8 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.5 M | 34.4 M | 34.4 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.2 M | 34.2 M | 34.2 M | 34.2 M | 34.1 M | 33.4 M | 33.3 M | 33.7 M | 33.3 M | 32.9 M | 32.9 M | 32.9 M | 31.1 M | 30.9 M | 30.9 M | 30.9 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 K | 24.4 K | 18.6 M | 17.9 M | 17.8 M | 17.7 M | 17.7 K | 17.7 M | 17.7 K | 17.7 K | 17.6 K | 17.6 M | 17.6 K | 17.6 K | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 17.6 K |
Net Income |
-3.24 M | -2.11 M | -1.98 M | -3.78 M | -4.15 M | - | -4.7 M | -6.56 M | -7.58 M | - | -4.63 M | -994 K | -3.48 M | - | -5.76 M | -5.43 M | -5.94 M | - | -4.22 M | -4.05 M | -4.9 M | - | -3.73 M | -4.69 M | -1.95 M | - | -4.37 M | -4.34 M | -5.61 M | -3.33 M | 68.5 M | -2.94 M | -935 K | -2.97 M | -1.24 M | -1.31 M | -1.68 M | -523 K | -965 K | -519 K | -1.94 M | -1.41 M | -1.59 M | -1.5 M | -876 K | -5.45 M | -2.98 M | 29 K | -9.81 M | -5.12 M | -4.34 M | -4.34 M | -4.34 M | 285 K | 617 K | 617 K | 617 K | -875 K | 109 K | 109 K | 109 K |
Revenue |
13.9 M | 12.5 M | 12.9 M | 11.4 M | 9.43 M | - | 11.5 M | 12.1 M | 10.2 M | - | 12 M | 13.6 M | 12.1 M | - | 9.11 M | 10.3 M | 12.5 M | - | 11.8 M | 11.2 M | 3 K | - | 10 K | 7 K | 216 K | 8.38 M | 327 K | 403 K | 423 K | 5.93 M | 135 K | - | - | 3.66 M | 2.65 M | 9.8 M | 8.39 M | 9.49 M | 10.1 M | 9.3 M | 7.78 M | 8.3 M | 7.82 M | 7.27 M | 6.13 M | 7.47 M | 6.79 M | 6.94 M | 6.48 M | 6.13 M | 5.79 M | 6.04 M | 5.7 M | 6.83 M | 6.67 M | 7.44 M | 6.73 M | 6.16 M | 6.26 M | 6.84 M | 6.15 M |
Cost of Revenue |
5.01 M | 4.56 M | 4.58 M | 4.29 M | 3.76 M | - | 4.53 M | 4.66 M | 4.3 M | - | 4 M | 4.29 M | 4.57 M | - | 3.36 M | 3.38 M | 4.27 M | - | 3.78 M | 3.69 M | 2.78 M | - | 2.23 M | 2.2 M | 2.01 M | - | 2.28 M | 1.98 M | 2.07 M | - | 1.15 M | 1.15 M | 1.18 M | - | 738 K | 4.76 M | 4.16 M | - | 5 M | 4.6 M | 4.45 M | - | 4.59 M | 4.13 M | 3.45 M | - | 4.87 M | 5.07 M | 3.73 M | - | 3.54 M | 3.81 M | 3.54 M | - | 3.78 M | 4.58 M | 3.94 M | - | 3.65 M | 3.8 M | 3.72 M |
Gross Profit |
8.87 M | 7.92 M | 8.3 M | 7.08 M | 5.66 M | - | 6.95 M | 7.49 M | 5.95 M | - | 7.98 M | 9.28 M | 7.57 M | - | 5.76 M | 6.91 M | 8.22 M | - | 8.06 M | 7.53 M | 5.86 M | - | 4.72 M | 2.09 M | 2.98 M | 5.56 M | 5.29 M | 4.67 M | 3.56 M | 3.56 M | 2.52 M | 2.54 M | 2.21 M | 2.7 M | 1.91 M | 1.57 M | 777 K | 4.83 M | 5.06 M | 4.7 M | 3.32 M | 3.51 M | 3.23 M | 3.14 M | 2.67 M | 2.44 M | 1.92 M | 1.88 M | 2.76 M | 2.57 M | 2.25 M | 2.23 M | 2.15 M | 2.79 M | 2.89 M | 2.86 M | 2.8 M | 2.65 M | 2.61 M | 3.04 M | 2.43 M |
Operating Income |
-1.81 M | -911 K | -832 K | -2.57 M | -3.05 M | - | -3.64 M | -5.55 M | -6.62 M | - | -4.64 M | -1.24 M | -5.61 M | - | -5.78 M | -5.98 M | -5.87 M | - | -3.97 M | -4.04 M | -4.74 M | - | -4.37 M | -6.17 M | -7.49 M | - | -4.76 M | -4.42 M | -5.73 M | - | -2.79 M | -2.93 M | -2.72 M | - | -2.83 M | -1.31 M | -1.74 M | - | -245 K | -510 K | -1.99 M | - | -1.81 M | -1.55 M | -2.27 M | - | -2.37 M | -1.75 M | 58 K | - | -475 K | -1.65 M | -665 K | - | 282 K | 240 K | 396 K | - | 248 K | 549 K | 585 K |
Interest Expense |
- | - | - | - | - | - | 24 K | -1 K | -21 K | - | -19 K | 543 K | 234 K | - | 1 K | 3 K | 8 K | - | 3 K | 2 K | 4 K | - | 25 K | 8 K | 6 K | - | - | - | - | - | 30 K | 38 K | 34 K | - | -105 K | 2 K | 57 K | - | -720 K | -9 K | 49 K | - | -40 K | -39 K | -40 K | - | -41 K | 1.41 M | -9.63 M | - | -54 K | -23 K | -89 K | - | -58 K | -58 K | -58 K | - | -42 K | -46 K | -52 K |
EBITDA |
-1.41 M | -709 K | - | - | -2.91 M | - | - | - | -6.46 M | - | - | - | -5.41 M | - | -5.09 M | -5.5 M | -5.65 M | - | -3.29 M | -3.6 M | -4.52 M | - | -3.71 M | -5.73 M | -7.28 M | - | -4.25 M | -4.11 M | -5.54 M | - | -2.73 M | -2.76 M | -2.52 M | - | -2.66 M | -1.13 M | -1.56 M | - | -44 K | -337 K | -1.81 M | - | -1.18 M | -1.13 M | -2.06 M | - | -1.71 M | -1.29 M | 290 K | - | 145 K | -1.23 M | -453 K | - | 922 K | 680 K | 620 K | - | 925 K | 1 M | 814 K |
Operating Expenses |
10.7 M | 8.84 M | 9.13 M | 9.66 M | 8.72 M | - | 10.6 M | 13 M | 12.6 M | - | 12.6 M | 13.2 M | 13.2 M | - | 11.5 M | 12.9 M | 14.1 M | - | 12 M | 11.6 M | 10.6 M | - | 9.1 M | 8.26 M | 10.5 M | - | 10 M | 9.1 M | 9.29 M | - | 5.31 M | 5.47 M | 4.93 M | - | 4.75 M | 6.35 M | 5.96 M | - | 5.31 M | 5.21 M | 5.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
5.28 M | 3.58 M | 3.66 M | 4.14 M | 3.38 M | - | 4.29 M | 4.84 M | 4.9 M | - | 4.84 M | 5.38 M | 5.26 M | - | 4.67 M | 4.54 M | 5.46 M | - | 4.61 M | 4.26 M | 3.72 M | - | 2.71 M | 2.19 M | 3.8 M | - | 3.84 M | 3.04 M | 2.96 M | - | 1.9 M | 2.21 M | 2.11 M | - | 2.01 M | 2.93 M | 2.4 M | - | 2.14 M | 2.02 M | 2.19 M | - | 2.1 M | 2 M | 2.22 M | - | 2.12 M | 1.6 M | 1.2 M | - | 1.17 M | 2.18 M | 1.21 M | - | 1.1 M | 1.12 M | 1.02 M | - | 996 K | 1.13 M | 1.1 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Apyx Medical Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
France
China
Israel
Britain
Canada
